Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06596473 · ClinicalTrials.gov registry record · Phase 1
A Study of BG-C477 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 20
- Study locations
NCT06596473: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by BeOne Medicines.
NCT06596473 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 310 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06596473, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
Primary Outcome
Number of participants with AEs and SAEs, including findings from abnormal laboratory assessments, and that meet protocol-defined dose-limiting toxicity (DLT) criteria or protocol-defined Adverse Event of Clinical Interest (AECI) criteria.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG Chemotherapy
- DRUG BG-C477
Study Locations (20)
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Northern Beaches Hospital - Frenchs Forest
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
- Beijing Chest Hospital, Capital Medical University - Beijing
California
- City of Hope National Medical Center - Duarte
Connecticut
- Yale University, Yale Cancer Center - New Haven
Kansas
- The University of Kansas Cancer Center - Westwood
New Jersey
- John Theurer Cancer Center Hackensack University Medical Center - Hackensack
Texas
- The University of Texas Md Anderson Cancer Center - Houston
Queensland
- Sunshine Coast University Private Hospital - Birtinya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2024-10-03 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06596473 shows while recruiting
NCT06596473 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.
NCT06596473 names 20 study sites across 18 states, led by New South Wales, Beijing Municipality, California.
Frequently Asked Questions
What is clinical trial NCT06596473 about?
NCT06596473 is a clinical study titled "A Study of BG-C477 in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
What is the current status of trial NCT06596473?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2024-10-03. Estimated completion is 2027-12-31.
What conditions does trial NCT06596473 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06596473?
The interventions under investigation include: Tislelizumab (DRUG), Chemotherapy (DRUG), BG-C477 (DRUG).
Who is sponsoring clinical trial NCT06596473?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06596473 being conducted?
This trial has 20 study locations across California, Connecticut, Kansas, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06596473's enrollment target sits among peer trials
310 24th of 144 higher than 121 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI